Cathepsin B inhibitor RC1 is a small-molecule that blocks the process of anthrax lethal toxin (LT) cytotoxicity, inhibits enzymatic activity of host cathepsin B that mediates the escape of toxins into the cytoplasm from late endosomes.

CAY10595 is a potent CRTH2/DP2 receptor antagonist that binds to the human receptor with a Ki of 10 nM.

Cazpaullone (9-Cyano-1-azapaullone) is a derivative of 1-Azakenpaullone, a potent, selective GSK3β inhibitor with IC50 of 8 nM, weakly inhibits CDK1/cyclin B and CDK5/p25 (IC50=0.5 and 0.3 uM).

CB-1158 (INCB-01158) is a potent, selective, oral available Arginase inhibitor with IC50 of 98 nM.

CB5305630 is a potent and noncompetitive IRE1 RNase inhibitor with IC50 of 60 nM in the FRET-derepression assay.

CB-618 (CB 238618) is a novel non-β-lactam β-lactamase inhibitor that potentiates meropenem MIC values against clinical Enterobacteriaceae isolates.

CB-618 (CB 238618) is a novel non-β-lactam β-lactamase inhibitor that potentiates meropenem MIC values against clinical Enterobacteriaceae isolates.

CB-6673567 is a potent, selective Adenylyl Cyclase 1 (AC1) inhibitor with IC50 of 77 uM, displays a 2- to 4-fold isoform selectivity over AC6.

CBB3001 (CBB-3001) is a novel potent, selective histone demethylase LSD1 inhibitor with IC50 of 21.25 uM.

CBK289001 (CBK-289001) is a small molecule inhibitor of Tartrate-resistant acid phosphatase (TRAP/ACP5), demonstrates efficacy in a migration assay and IC50 values from 4 to 125 uM..

CC-122 is a novel agent for DLBCL with antitumor and immunomodulatory activity.CC-122 binds CRBN and degrades Aiolos and Ikaros resulting in a mimicry of IFN signaling and apoptosis in DLBCL.

CC-671 is a potent, selective, dual TTK (Mps1)/CLK2 inhibitor with IC50 of 5/3 nM, respectively.

CC-885 (CC 885, CC885) is a novel E3 ligase cereblon (CRBN) modulator with potent anti-tumour activity mediated through the degradation of GSPT1.

CC-90003 (CC90003) is a potent and selective, covalent ERK1/2 inhibitor with IC50 of 10-20 nM, demonstrates excellent selectivity in a 258-kinase biochemical assay panel.

CCC07-01 (CCC 0701) is a novel alkylating compound that is capable of disrupting expression of PD-1, PD-L1 and CTLA-4 genes with IC50 of 15, 10 and 5 nM in cell-base assays.

CCG 102487 is a CCG-2979 analog that reduces streptokinase (SK) activity with little inhibition of group A streptococcal (GAS) growth.

CCG 2979 is a small molecule inhibitor of gene expression of streptokinase (SK), a critical group A streptococcal (GAS) virulence factor.

CCG-222740 (CCG222740) is a pharmacological inhibitor of MRTF/SRF signalling, shows greater inhibitory effect on MRTF/SRF target genes than MRTF-A inhibitor CCG-203971, with IC50 of 5 uM in fibroblast-mediated collagen contraction assay.

CCG-232601 is a potent (IC50=0.55 uM), orally bioavailable Rho/MKL1/SRF transcriptional pathway that target transcriptional factor MRTF.

CCG-50014 is the most potent against the regulator of G-protein signaling protein type 4 (RGS4) (IC50 =30 nM) and is >20-fold selective for RGS4 over other RGS proteins. CCG-50014 binds covalently to the RGS, forming an adduct on two cysteine residues located in an allosteric regulatory site. CCG50014, reduces nociceptive responses and enhances opioid-mediated analgesic effects in the mouse formalin test.

CCG-63802 is a reversible inhibitor of regulator of G-protein signaling (RGS) protein; with greatest potency at RGS4. IC50 value: Target: RGS CCG-63802 is selective amongst RGS proteins, with greatest potency at RGS4.

CCG-63808 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins.